Jaap Goudsmit, M.D., Ph.D., is a Dutch scientist, well-known for his research in the fields of HIV and influenza. During his career, Goudsmit published 560 scientific publications in peer-reviewed journals, nine of which appeared in Science, most recently in 2017, and six in Nature. Goudsmit was among the first in 1986 to discover that the amount of HIV in the blood predicted progression to clinical A.I.D.S. In 1989 Goudsmit discovered that HIV neutralizing antibodies target the V3 loop in the HIV envelope, a component closely linked with the virulence of HIV.
In 2002 Goudsmit joined Crucell, a biotechnology company in Leiden, Netherlands, as chief medical officer and executive vice-president of vaccine research and development. He and his team discovered adenovirus vector-based vaccines against Ebola and HIV, and a monoclonal antibody cocktail against rabies. Goudsmit discovered influenza hemagglutinin stem antibodies, which protect against A and B strains of Influenza, in 2006.
When Crucell was acquired by Johnson & Johnson in 2011, Goudsmit became head of the Crucell Vaccine Institute of Janssen, an institute focusing on influenza vaccine research. In 2015, he became global head of the Janssen Prevention Center, that focuses on the prevention of non-communicable diseases with a special emphasis on prognostic markers for age-related diseases. In 2017, Goudsmit retired from Johnson & Johnson.
Goudsmit was professor of virology from 1989-2001 at the University of Amsterdam, where he was one of the principal investigators of the Amsterdam Cohort Studies on HIV infection and AIDS among homosexual men and IV drug users. From 2001-2016, he was professor of vaccinology and immunoprophylaxis at the University of Amsterdam. In 2016, Goudsmit was appointed adjunct professor of epidemiology at the Harvard T.H. Chan School of Public Health. In 2016, Goudsmit also received an honorary degree from Vrije University and the Vrije University Medical Center (Netherlands) for his lifetime of scientific achievements in both academia and the biopharmaceutical industry.